Aurinia Pharmace Financials
Aurinia Pharmace (AUPH) reported $283.1M in revenue for fiscal year 2025, up 20.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Lower overhead turned Aurinia’s high-gross-margin business into a real cash generator, enabling buybacks without balance-sheet strain.
FY2025 net income of$287.2M ran far above operating income of$104.9M , so the headline profit jump was helped materially by items below operations rather than by core selling economics alone. Operating cash flow of$135.7M is therefore the cleaner proof that the business crossed from burn to internally funded operations.
The turnaround looks mainly like an overhead reset, not a manufacturing improvement: gross margin remained extremely high at
Buybacks were funded from the business rather than from added financial strain, with
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Aurinia Pharmace's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aurinia Pharmace has an operating margin of 37.1%, meaning the company retains $37 of operating profit per $100 of revenue. This results in a moderate score of 51/100, indicating healthy but not exceptional operating efficiency. This is up from -2.0% the prior year.
Aurinia Pharmace's revenue surged 20.4% year-over-year to $283.1M, reflecting rapid business expansion. This strong growth earns a score of 88/100.
Aurinia Pharmace carries a low D/E ratio of 0.29, meaning only $0.29 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 69/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.25, Aurinia Pharmace holds $5.25 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 91/100.
Not available for Aurinia Pharmace, and counted as zero in the overall score.
Aurinia Pharmace's ROE of 49.4% shows moderate profitability relative to equity, earning a score of 40/100. This is up from 1.5% the prior year.
Aurinia Pharmace scores 7.85, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.2B) relative to total liabilities ($170.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aurinia Pharmace passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Aurinia Pharmace generates $0.47 in operating cash flow ($135.7M OCF vs $287.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Aurinia Pharmace earns $24.23 in operating income for every $1 of interest expense ($104.9M vs $4.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Aurinia Pharmace generated $283.1M in revenue in fiscal year 2025. This represents an increase of 20.4% from the prior year.
Aurinia Pharmace's EBITDA was $124.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 742.7% from the prior year.
Aurinia Pharmace reported $287.2M in net income in fiscal year 2025. This represents an increase of 4851.7% from the prior year.
Aurinia Pharmace earned $2.07 per diluted share (EPS) in fiscal year 2025. This represents an increase of 5075.0% from the prior year.
Cash & Balance Sheet
Aurinia Pharmace held $80.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Aurinia Pharmace's gross margin was 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.
Aurinia Pharmace's operating margin was 37.1% in fiscal year 2025, reflecting core business profitability. This is up 39.0 percentage points from the prior year.
Aurinia Pharmace's ROE was 49.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 47.9 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Aurinia Pharmace invested $32.5M in research and development in fiscal year 2025. This represents an increase of 56.4% from the prior year.
Aurinia Pharmace spent $98.2M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 143.9% from the prior year.
Not reported for fiscal year 2025.
AUPH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $311.5M | $283.1M+20.4% | $235.1M+34.0% | $175.5M+31.0% | $134.0M+193.9% | $45.6M-9.0% | $50.1M+15660.4% | $318K-31.3% | $463K |
| Cost of Revenue | N/A | $32.7M+15.6% | $28.2M+99.7% | $14.1M+149.8% | $5.7M+419.2% | $1.1M | $0 | $0 | N/A |
| Gross Profit | N/A | $250.4M+21.0% | $206.9M+28.2% | $161.4M+25.7% | $128.4M+188.4% | $44.5M-11.2% | $50.1M+15660.4% | $318K | N/A |
| R&D Expenses | N/A | $32.5M+56.4% | $20.8M-58.1% | $49.6M+10.3% | $45.0M-12.0% | $51.1M+1.6% | $50.3M-4.8% | $52.9M+27.8% | $41.4M |
| SG&A Expenses | N/A | $101.8M-40.8% | $172.0M-11.8% | $195.0M-0.7% | $196.4M+13.2% | $173.5M+78.3% | $97.3M+336.3% | $22.3M+62.8% | $13.7M |
| Operating Income | $150.7M | $104.9M+2338.4% | -$4.7M+94.9% | -$91.7M+17.7% | -$111.5M+38.3% | -$180.7M-73.3% | -$104.3M-14.7% | -$90.9M-64.6% | -$55.2M |
| Interest Expense | N/A | $4.3M-10.4% | $4.8M+74.2% | $2.8M | $0 | $0 | N/A | N/A | N/A |
| Income Tax | N/A | -$173.0M-10303.1% | $1.7M+207.8% | $551K-69.9% | $1.8M+140.5% | $760K+908.5% | -$94K-165.3% | $144K+97.3% | $73K |
| Net Income | $314.1M | $287.2M+4851.7% | $5.8M+107.4% | -$78.0M+27.9% | -$108.2M+40.2% | -$181.0M-76.3% | -$102.7M-16.2% | -$88.4M-66.5% | -$53.1M |
| EPS (Diluted) | $2.29 | $2.07+5075.0% | $0.04+107.4% | -$0.54+28.9% | -$0.76+45.7% | -$1.40-60.9% | -$0.87+8.4% | -$0.95 | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AUPH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $751.6M+36.5% | $550.6M+0.5% | $548.1M+16.4% | $470.9M-13.3% | $543.4M+17.2% | $463.7M+43.0% | $324.3M | N/A |
| Current Assets | $492.0M+10.2% | $446.6M+5.1% | $424.8M-4.0% | $442.5M-13.8% | $513.3M+22.4% | $419.4M+33.1% | $315.1M | N/A |
| Cash & Equivalents | $80.2M-3.9% | $83.4M+71.1% | $48.8M-48.2% | $94.1M-59.4% | $231.6M-14.9% | $272.4M-11.0% | $306.0M+159.4% | $118.0M |
| Inventory | $45.7M+16.5% | $39.2M-1.2% | $39.7M+60.4% | $24.8M+28.1% | $19.3M+38.8% | $13.9M | $0 | N/A |
| Total Liabilities | $170.3M-1.7% | $173.2M+1.8% | $170.1M+160.0% | $65.4M+1.8% | $64.3M+15.0% | $55.9M+117.5% | $25.7M | N/A |
| Current Liabilities | $93.7M-4.1% | $97.8M+26.7% | $77.2M+67.4% | $46.1M+13.4% | $40.6M+27.0% | $32.0M+183.3% | $11.3M | N/A |
| Total Equity | $581.3M+54.0% | $377.5M-0.1% | $378.0M-6.8% | $405.4M-15.4% | $479.1M+17.5% | $407.8M+36.6% | $298.6M+120.0% | $135.7M |
| Retained Earnings | -$649.4M+30.7% | -$936.6M+0.6% | -$942.3M-9.0% | -$864.3M-14.3% | -$756.1M-31.5% | -$575.2M-21.7% | -$472.5M | N/A |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
AUPH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $175.2M | $135.7M+205.6% | $44.4M+232.7% | -$33.5M+57.9% | -$79.5M+49.6% | -$157.7M-125.7% | -$69.9M-9.9% | -$63.6M-23.2% | -$51.6M |
| Investing Cash Flow | $12.8M | -$32.8M-183.5% | $39.3M+685.5% | -$6.7M+88.9% | -$60.6M+41.6% | -$103.9M+34.3% | -$158.2M-2132.5% | $7.8M+12073.8% | -$65K |
| Financing Cash Flow | -$61.3M | -$106.1M-116.1% | -$49.1M-857.0% | -$5.1M-310.9% | $2.4M-98.9% | $221.1M+13.8% | $194.4M-20.3% | $243.9M+5975.1% | $4.0M |
| Share Buybacks | $83.6M | $98.2M+143.9% | $40.2M | $0 | $0 | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AUPH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5%+0.5pp | 88.0%-3.9pp | 91.9%-3.8pp | 95.8%-1.8pp | 97.6%-2.4pp | 100.0%0.0pp | 100.0% | N/A |
| Operating Margin | 37.1%+39.0pp | -2.0%+50.2pp | -52.2%+30.9pp | -83.2% | -396.3% | -208.1% | -28598.4% | -11930.9% |
| Net Margin | 101.5% | 2.5%+46.9pp | -44.4%+36.3pp | -80.7% | -396.9% | -204.9% | -27794.0% | -11464.1% |
| Return on Equity | 49.4%+47.9pp | 1.5%+22.2pp | -20.6%+6.1pp | -26.7%+11.1pp | -37.8%-12.6pp | -25.2%+4.4pp | -29.6%+9.5pp | -39.1% |
| Return on Assets | 38.2%+37.2pp | 1.1%+15.3pp | -14.2%+8.8pp | -23.0%+10.3pp | -33.3%-11.2pp | -22.1%+5.1pp | -27.3% | N/A |
| Current Ratio | 5.25+0.7x | 4.57-0.9x | 5.50-4.1x | 9.60-3.0x | 12.63-0.5x | 13.11-14.8x | 27.90 | N/A |
| Debt-to-Equity | 0.29-0.2x | 0.460.0x | 0.45+0.3x | 0.160.0x | 0.130.0x | 0.14+0.1x | 0.09 | N/A |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Aurinia Pharmace Ranks
Frequently Asked Questions
What is Aurinia Pharmace's annual revenue?
Aurinia Pharmace (AUPH) reported $283.1M in total revenue for fiscal year 2025. This represents a 20.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aurinia Pharmace's revenue growing?
Aurinia Pharmace (AUPH) revenue grew by 20.4% year-over-year, from $235.1M to $283.1M in fiscal year 2025.
Is Aurinia Pharmace profitable?
Yes, Aurinia Pharmace (AUPH) reported a net income of $287.2M in fiscal year 2025.
What is Aurinia Pharmace's EBITDA?
Aurinia Pharmace (AUPH) had EBITDA of $124.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aurinia Pharmace's gross margin?
Aurinia Pharmace (AUPH) had a gross margin of 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Aurinia Pharmace's operating margin?
Aurinia Pharmace (AUPH) had an operating margin of 37.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Aurinia Pharmace's return on equity (ROE)?
Aurinia Pharmace (AUPH) has a return on equity of 49.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aurinia Pharmace's operating cash flow?
Aurinia Pharmace (AUPH) generated $135.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Aurinia Pharmace's total assets?
Aurinia Pharmace (AUPH) had $751.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Aurinia Pharmace spend on research and development?
Aurinia Pharmace (AUPH) invested $32.5M in research and development during fiscal year 2025.
What is Aurinia Pharmace's current ratio?
Aurinia Pharmace (AUPH) had a current ratio of 5.25 as of fiscal year 2025, which is generally considered healthy.
What is Aurinia Pharmace's debt-to-equity ratio?
Aurinia Pharmace (AUPH) had a debt-to-equity ratio of 0.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aurinia Pharmace's return on assets (ROA)?
Aurinia Pharmace (AUPH) had a return on assets of 38.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aurinia Pharmace's Altman Z-Score?
Aurinia Pharmace (AUPH) has an Altman Z-Score of 7.85, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aurinia Pharmace's Piotroski F-Score?
Aurinia Pharmace (AUPH) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aurinia Pharmace's earnings high quality?
Aurinia Pharmace (AUPH) has an earnings quality ratio of 0.47x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aurinia Pharmace cover its interest payments?
Aurinia Pharmace (AUPH) has an interest coverage ratio of 24.23x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Aurinia Pharmace?
Aurinia Pharmace (AUPH) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.